Study guide
8.1 Asthma & COPD Management
DHA Pharmacist Licensing Assessment PHO5481
Track your progress as you read
Finished sections get a check mark.
1 Exam Overview & Licensing Pathway
1.1 Current Exam Facts & Format 1.2 Eligibility, PQR & the Sheryan Application Process 1.3 Study Strategy & Test-Day Plan
2 Cardiovascular Pharmacology
2.1 Antihypertensives & RAAS Agents 2.2 Heart Failure & Antiarrhythmic Drugs 2.3 Lipid-Lowering & Antianginal Agents
3 Endocrine & Metabolic Pharmacology
3.1 Insulin & Oral Antidiabetic Agents 3.2 Thyroid, Bone & Calcium Agents 3.3 Corticosteroids & Other Hormonal Agents
4 Anti-Infective Pharmacology
4.1 Beta-Lactam Antibiotics 4.2 Non-Beta-Lactam Antibacterials 4.3 Antifungals, Antivirals & Antituberculars
5 CNS, Psychiatric & Pain Pharmacology
5.1 Psychiatric Pharmacology 5.2 Antiepileptics & Neurologic Agents 5.3 Analgesics: NSAIDs, Opioids & Migraine
6 Respiratory, GI & Hematology Pharmacology
6.1 Respiratory Pharmacology 6.2 Gastrointestinal Pharmacology 6.3 Anticoagulants, Antiplatelets & Hematology Agents
7 Pharmaceutical Care: Cardiometabolic Disease
7.1 Diabetes Management & Counseling 7.2 Hypertension & Dyslipidemia Management 7.3 Heart Failure & Anticoagulation Management
8 Pharmaceutical Care: Respiratory, Rheumatology & Infection
8.1 Asthma & COPD Management 8.2 Gout, Pain & Rheumatologic Care 8.3 Infection Management & Antimicrobial Stewardship
9 Counseling, Monitoring & Special Populations
9.1 Patient Counseling, Adherence & Health Literacy 9.2 Therapeutic Monitoring & Laboratory Interpretation 9.3 Pregnancy, Pediatrics, Geriatrics & Organ Impairment 9.4 Pharmacoeconomics & Formulary Decision Making
10 Pharmaceutical Calculations I
10.1 Concentration, Ratio & Percentage Strength 10.2 Weight-Based & BSA Dosing 10.3 Dilution, Concentration & Alligation
11 Pharmaceutical Calculations II
11.1 Infusion Rates & IV Flow Calculations 11.2 Dispensing Quantities & Days' Supply 11.3 Compounding Calculations, Isotonicity & Milliequivalents
12 UAE Pharmacy Law & Regulation
12.1 UAE Regulatory Framework & Licensing Authorities 12.2 Medicine Registration, Pricing & Supply Chain 12.3 Prescription Requirements & Validity
13 Controlled Drugs, Ethics & Pharmacovigilance
13.1 Controlled & Semi-Controlled Medicines in the UAE 13.2 Ethics, Confidentiality & Generic Substitution 13.3 Pharmacovigilance, Recall & Medicine Disposal
14 Pharmacokinetics I: ADME
14.1 Absorption & Bioavailability 14.2 Distribution & Protein Binding 14.3 Metabolism & Elimination
15 Pharmacokinetics II: Kinetics, Dosing & TDM
15.1 Half-Life, Clearance & Kinetic Order 15.2 Loading & Maintenance Dosing 15.3 Therapeutic Drug Monitoring
16 OTC Medicines & Self-Care
16.1 Cough, Cold & Allergic Rhinitis 16.2 GI Self-Care: Heartburn, Constipation & Diarrhoea 16.3 Pain & Fever Self-Care 16.4 Referral Red Flags, Emergency Contraception & Skin
17 Medication Safety
17.1 High-Alert Medications & Error-Prone Abbreviations 17.2 Medication Reconciliation & Duplicate Therapy 17.3 Adverse Drug Reactions & Hypersensitivity Recognition
18 Sterile & Nonsterile Compounding
18.1 Aseptic Technique & Compounding Environments 18.2 Parenteral, TPN & Cytotoxic Preparation 18.3 Nonsterile Compounding
19 Pharmaceutics, Biopharmaceutics & Toxicology
19.1 Dosage Form Design & the Biopharmaceutics Classification System 19.2 Dissolution & Excipients 19.3 Toxicology: Poisoning Recognition & Antidotes
20 Infection Control, Natural Products, Medicinal Chemistry & Pharmacogenomics
20.1 Infection Control & Immunization 20.2 Pharmacognosy & Dietary Supplements 20.3 Medicinal Chemistry Essentials 20.4 Clinical Pharmacogenomics
8.1 Asthma & COPD Management
Key Takeaways Explain This Topic AI
Dispensing more than 2 short-acting beta-agonist (SABA) canisters per year signals uncontrolled asthma and increased exacerbation risk; GINA recommends ICS-containing therapy at every step, never SABA-only treatment
The Asthma Control Test (ACT) scores 5–25; a score below 20 suggests asthma that is not well controlled and should trigger a medication and adherence review
COPD is confirmed spirometrically by a post-bronchodilator FEV1/FVC ratio below 0.7; GOLD groups patients as A, B, or E based on symptoms and exacerbation history
LABA + LAMA is the backbone for GOLD group E; add an inhaled corticosteroid when blood eosinophils are 300 cells/µL or higher or the patient is a frequent exacerbator
- In acute COPD exacerbations, controlled oxygen targeting SpO2 88–92% prevents hypercapnic respiratory failure
- Last updated: August 2026
Pharmacist-Led Asthma Care
Asthma is a chronic inflammatory airway disease whose day-to-day outcomes depend far more on assessment, adherence, and inhaler technique than on any single drug. The DHA exam expects you to think like a disease-state manager: assess control, identify red flags, apply stepwise logic, and counsel.
Assessing Asthma Control
Assess two domains at every review:
Symptom control : daytime symptoms more than twice a week, night waking, activity limitation, and reliever use more than twice a week all point to inadequate control.
Future risk : previous exacerbations, poor adherence, incorrect inhaler technique, comorbid rhinitis, smoking, obesity, and low lung function.
A classic exam red flag is SABA overuse . Dispensing more than 2 short-acting beta-agonist (SABA, e.g., salbutamol) 200-dose canisters per year is associated with an increased risk of exacerbation, and use averaging one or more canisters per month is associated with a markedly increased risk of asthma death. The community pharmacist is uniquely placed to spot over-ordering at the dispensing counter and refer for review.
The Asthma Control Test (ACT) is a validated 5-item questionnaire covering daytime symptoms, night waking, activity limitation, reliever use, and self-rated control, scoring 5 to 25; a score of 20 or above suggests well-controlled asthma, while a score below 20 should prompt review of adherence, technique, and controller therapy.
Stepwise Therapy — the GINA Concept
The cornerstone of the Global Initiative for Asthma (GINA) strategy is that inhaled corticosteroid (ICS)-containing therapy is recommended at every step — SABA-only treatment is no longer advised, even for mild asthma, because it treats symptoms without addressing the underlying inflammation and leaves patients exposed to exacerbation risk.
Track 1 (preferred) : low-dose ICS-formoterol used as the reliever, with or without maintenance dosing. In steps 3–5 this becomes MART (maintenance and reliever therapy), where a single ICS-formoterol inhaler is used both daily and for symptom relief, simplifying regimens and reducing severe exacerbations compared with conventional ICS-LABA plus SABA.
Track 2 (alternative) : daily maintenance ICS (or ICS-LABA at higher steps) with a SABA reliever taken as needed.
Before stepping up, always check adherence and technique and address modifiable risk factors; after about 3 months of good control, consider stepping down to the lowest dose that maintains control, keeping the patient on some ICS-containing therapy.
Inhaler Technique, Devices, Spacers, and Action Plans
Check technique at every opportunity; common errors include poor actuation–inhalation coordination, no breath-hold, failure to exhale before inhaling, and inadequate inspiratory effort.
Device selection matters : dry-powder inhalers require a sufficiently forceful inhalation, so frail or elderly patients with low inspiratory flow may do better with a pressurised metered-dose inhaler (pMDI) plus spacer.
Spacers with pMDIs improve lung deposition, reduce oropharyngeal ICS side effects (candidiasis, dysphonia), and are especially valuable in children and the elderly. Advise rinsing the mouth and spitting after ICS doses, and washing spacers with detergent and air-drying to reduce static.
Every patient should have a written personalised asthma action plan : how to recognise deterioration, how to adjust reliever and controller doses, when to start oral corticosteroids, and when to seek urgent care.
Managing Exacerbations
An exacerbation is managed with frequent SABA (preferably via spacer), early short-course oral prednisolone 40–50 mg daily for 5–7 days in adults, and controlled oxygen. Escalate to emergency care if the patient cannot speak in sentences, has a peak flow below 50% of best or predicted, oxygen saturation below 92%, or a silent chest. Arrange follow-up within a week of discharge and revise the action plan. Address triggers (house dust mite, pollen, tobacco smoke, occupational sensitizers) and support smoking cessation with behavioural support plus pharmacotherapy such as nicotine replacement therapy, varenicline, or bupropion.
COPD: Diagnosis and Assessment
Chronic obstructive pulmonary disease (COPD) is confirmed by spirometry showing a post-bronchodilator FEV1/FVC ratio below 0.7 , indicating persistent airflow limitation; the FEV1 percentage then grades severity. Suspect it in symptomatic patients (chronic cough, sputum production, progressive dyspnoea) with a smoking or biomass-fuel exposure history.
GOLD ABE Grouping and Inhaled Therapy
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) groups patients by symptoms (mMRC breathlessness score or CAT score) and exacerbation history:
- Group Exacerbations Symptoms Initial inhaled therapy
- A 0–1 moderate, none hospitalising Fewer A bronchodilator
- B 0–1 moderate, none hospitalising More LABA + LAMA
- E ≥2 moderate or ≥1 hospitalising Any LABA + LAMA; add ICS if eosinophils ≥300 cells/µL
The long-acting muscarinic antagonist/long-acting beta-agonist (LAMA/LABA) combination is the backbone for groups B and E. ICS is added for frequent exacerbators with blood eosinophils ≥300 cells/µL , where benefit is greatest; weigh this against the ICS-associated pneumonia risk, and consider withdrawal of ICS if pneumonia occurs without a strong exacerbation indication. Follow-up is guided by treatable traits — persistent dyspnoea versus recurrent exacerbations — with inhaler technique rechecked at every step.
Beyond Inhalers
Pulmonary rehabilitation improves exercise capacity and quality of life and reduces hospital admissions — refer every symptomatic patient.
Vaccination : influenza, pneumococcal, and COVID-19 vaccines are recommended for all patients with COPD; smoking cessation remains the single most effective disease-modifying intervention.
Selected patients with chronic productive cough may benefit from mucolytics ; long-term oxygen therapy is reserved for those meeting severe resting hypoxaemia criteria assessed by arterial blood gases.
Exacerbations : increase short-acting bronchodilators, give oral prednisolone 40 mg daily for 5 days , and add an antibiotic (e.g., amoxicillin or doxycycline for 5–7 days) when there is increased dyspnoea plus increased sputum volume and purulence (the Anthonisen criteria).
Controlled oxygen : in acute exacerbations target SpO2 88–92% to avoid worsening hypercapnia in CO2 retainers — a frequently tested number.